5 Best Large-Cap Biotech Stocks To Buy Now

2. Gilead Sciences, Inc. (NASDAQ:GILD)

No of HFs: 61

Total Value of HF Holdings: $1.9 Billion

Gilead Sciences, Inc. is a research-based biopharmaceutical company that focuses on the development of therapeutics to advance the care of patients that suffer from HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions. During the third quarter of 2020, the company reported a revenue of $6.6 billion, up 17% compared to $5.6 billion during the same quarter of 2019.

Why Gilead Sciences, Inc stock is a compelling investment case? In an article, Tao Value highlighted a few stocks where GILD was one of them,

“On the detracting side, our largest detractor is Gilead Sciences (ticker: GILD), which dragged 104 bps. Gilead reported a lackluster Q2, falling short of earning estimate by relatively large margin. It however it raised its full year revenue and earning guidance, possibly due to incremental Remdesivir revenue in 2nd half year. Gilead also announced a big acquisition of Immunomedics for $21 billion. Through this acquisition, Gilead will add Immunomedics’ crown asset Trodelvy to its oncology pipeline and expect it could be significantly accretive to earnings since 2023. The share price decline might be due to COVID19 themed traders seek exit after a good run. I didn’t see changes to our original thesis.”